Ultragenyx Pharma (NASDAQ: RARE) reported Q2 EPS of ($0.90), $0.32 better than the analyst estimate of ($1.22). Revenue for the quarter came in at $214 million versus the consensus estimate of $182.1 million.

Outlook:-

Full year 2026 total revenue guidance of $730 million to $760 million vs consensus $741.9 million.

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.